|
|
||||||||
Ann Thorac Surg 1996;62:1659-1668
© 1996 The Society of Thoracic Surgeons
Good Samaritan Hospital, Portland, Oregon; Cardiothoracic and Vascular Surgeons, Austin, Texas; Heart and Lung Surgical Associates, Portland, Maine; Sentara Norfolk General Hospital, Norfolk, Virginia; The Carolinas Heart Institute, Charlotte, North Carolina; Southwestern Cardiovascular Surgical Associates, Lubbock, Texas; University of Texas Health Science Center, San Antonio, Texas; University of Arizona College of Medicine, Tucson, Arizona; Ochsner Clinic, New Orleans, Louisiana; Sharp Memorial Hospital, San Diego, California; University of Texas Southwestern Medical Center, Dallas, Texas; Baylor College of Medicine, Houston, Texas; and Brigham and Women's Hospital, Boston, Massachusetts
Background. High-dose aprotinin reduces transfusion requirements in patients undergoing coronary artery bypass grafting, but the safety and effectiveness of smaller doses is unclear. Furthermore, patient selection criteria for optimal use of the drug are not well defined.
Methods. Seven hundred and four first-time coronary artery bypass grafting patients were randomized to receive one of three doses of aprotinin (high, low, and pump-primeonly) or placebo. The patients were stratified as to risk of excessive bleeding.
Results. All three aprotinin doses were highly effective in reducing bleeding and transfusion requirements. Consistent efficacy was not, however, demonstrated in the subgroup of patients at low risk for bleeding. There were no differences in mortality or the incidences of renal failure, strokes, or definite myocardial infarctions between the groups, although the pump-primeonly dose was associated with a small increase in definite, probable, or possible myocardial infarctions (p = 0.045).
Conclusions. Low-dose and pump-primeonly aprotinin regimens provide reductions in bleeding and transfusion requirements that are similar to those of high-dose regimens. Although safe, aprotinin is not routinely indicated for the first-time coronary artery bypass grafting patient who is at low risk for postoperative bleeding. The pump-primeonly dose is not currently recommended because of a possible association with more frequent myocardial infarctions.
Related Articles
Ann. Thorac. Surg. 1996 62: 1575-1577.
Ann. Thorac. Surg. 1996 62: 1667-1668.
This article has been cited by other articles:
![]() |
D. R. McIlroy, P. S. Myles, L. E. Phillips, and J. A. Smith Antifibrinolytics in cardiac surgical patients receiving aspirin: a systematic review and meta-analysis Br. J. Anaesth., February 1, 2009; 102(2): 168 - 178. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Nurozler, T. Kutlu, and G. Kucuk Aprotinin for Patients Exposed to Clopidogrel Before Off-Pump Coronary Bypass Asian Cardiovasc Thorac Ann, December 1, 2008; 16(6): 483 - 487. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Westaby Aprotinin: Twenty-five years of claim and counterclaim J. Thorac. Cardiovasc. Surg., March 1, 2008; 135(3): 487 - 491. [Full Text] [PDF] |
||||
![]() |
M. D. McEvoy, S. T. Reeves, J. G. Reves, and F. G. Spinale Aprotinin in Cardiac Surgery: A Review of Conventional and Novel Mechanisms of Action Anesth. Analg., October 1, 2007; 105(4): 949 - 962. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Veres, T. Radovits, H. Schultz, L.-n. Lin, J. Hutter, E. Weigang, Z. Szabolcs, and G. Szabo Effect of recombinant aprotinin on postoperative blood loss and coronary vascular function in a canine model of cardiopulmonary bypass Eur. J. Cardiothorac. Surg., August 1, 2007; 32(2): 340 - 345. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Brown, N. J.O. Birkmeyer, and G. T. O'Connor Meta-Analysis Comparing the Effectiveness and Adverse Outcomes of Antifibrinolytic Agents in Cardiac Surgery Circulation, June 5, 2007; 115(22): 2801 - 2813. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Mannucci and M. Levi Prevention and Treatment of Major Blood Loss N. Engl. J. Med., May 31, 2007; 356(22): 2301 - 2311. [Full Text] [PDF] |
||||
![]() |
The Society of Thoracic Surgeons Blood Conservatio, V. A. Ferraris, S. P. Ferraris, S. P. Saha, E. A. Hessel II, C. K. Haan, B. D. Royston, C. R. Bridges, R. S.D. Higgins, G. Despotis, et al. Perioperative Blood Transfusion and Blood Conservation in Cardiac Surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists Clinical Practice Guideline Ann. Thorac. Surg., May 1, 2007; 83(5_Supplement): S27 - S86. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ouattara, H. Bouzguenda, Y. Le Manach, P. Leger, A. Mercadier, P. Leprince, N. Bonnet, G. Montalescot, B. Riou, and P. Coriat Impact of aspirin with or without clopidogrel on postoperative bleeding and blood transfusion in coronary surgical patients treated prophylactically with a low-dose of aprotinin Eur. Heart J., April 12, 2007; (2007) ehm049v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ronald and J. Dunning Does use of aprotinin decrease the incidence of stroke and neurological complications in adult patients undergoing cardiac surgery? Interactive CardioVascular and Thoracic Surgery, December 1, 2006; 5(6): 767 - 773. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Body and C. D. Mazer Pro: Aprotinin Has a Good Efficacy and Safety Profile Relative to Other Alternatives for Prevention of Bleeding in Cardiac Surgery Anesth. Analg., December 1, 2006; 103(6): 1354 - 1359. [Full Text] [PDF] |
||||
![]() |
W. Dietrich, R. Busley, and M. Kriner High-Dose Aprotinin in Cardiac Surgery: Is High-Dose High Enough?: An Analysis of 8281 Cardiac Surgical Patients Treated with Aprotinin Anesth. Analg., November 1, 2006; 103(5): 1074 - 1081. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Cooper Jr, J. Abrams, O.H. Frazier, R. Radovancevic, B. Radovancevic, A. W. Bracey, M. J. Kindo, and I. D. Gregoric Fatal pulmonary microthrombi during surgical therapy for end-stage heart failure: Possible association with antifibrinolytic therapy J. Thorac. Cardiovasc. Surg., May 1, 2006; 131(5): 963 - 968. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Pleym, A. Wahba, V. Videm, A. Asberg, S. Lydersen, L. Bjella, O. Dale, and R. Stenseth Increased fibrinolysis and platelet activation in elderly patients undergoing coronary bypass surgery. Anesth. Analg., March 1, 2006; 102(3): 660 - 667. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. L.K. Leung Perioperative Evaluation of Bleeding Diathesis Hematology, January 1, 2006; 2006(1): 457 - 461. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G Raja and G. D Dreyfus Modulation of Systemic Inflammatory Response after Cardiac Surgery Asian Cardiovasc Thorac Ann, December 1, 2005; 13(4): 382 - 395. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Vanek, M. Jares, R. Fajt, Z. Straka, K. Jirasek, M. Kolesar, P. Brucek, and M. Maly Fibrinolytic inhibitors in off-pump coronary surgery: a prospective, randomized, double-blind TAP study (tranexamic acid, aprotinin, placebo) Eur. J. Cardiothorac. Surg., October 1, 2005; 28(4): 563 - 568. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. O. Morgan Cost, quality, and risk: Measuring and stopping the hidden costs of coronary artery bypass graft surgery Am. J. Health Syst. Pharm., September 15, 2005; 62(18_Supplement_4): S2 - S5. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kher, K. K. Meldrum, K. L. Hile, M. Wang, B. M. Tsai, M. W. Turrentine, J. W. Brown, and D. R. Meldrum Aprotinin improves kidney function and decreases tubular cell apoptosis and proapoptotic signaling after renal ischemia-reperfusion J. Thorac. Cardiovasc. Surg., September 1, 2005; 130(3): 662 - 662. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Fergusson, K. C. Glass, B. Hutton, and S. Shapiro Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? Clinical Trials, June 1, 2005; 2(3): 218 - 232. [Abstract] [PDF] |
||||
![]() |
A. M. Mahdy and N. R. Webster Perioperative systemic haemostatic agents Br. J. Anaesth., December 1, 2004; 93(6): 842 - 858. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sedrakyan, T. Treasure, and J. A. Elefteriades Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: A systematic review and meta-analysis of randomized clinical trials J. Thorac. Cardiovasc. Surg., September 1, 2004; 128(3): 442 - 448. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. K. Smith, S. K. Datta, L. H. Muhlbaier, G. Samsa, A. Nadel, and J. Lipscomb Cost analysis of aprotinin for coronary artery bypass patients: analysis of the randomized trials Ann. Thorac. Surg., February 1, 2004; 77(2): 635 - 642. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Genoni, R. Tavakoli, C. Hofer, O. Bertel, and M. Turina Clopidogrel before urgent coronary artery bypass graft J. Thorac. Cardiovasc. Surg., July 1, 2003; 126(1): 288 - 289. [Full Text] [PDF] |
||||
![]() |
A. D. Grayson, M. Khater, M. Jackson, and M. A. Fox Valvular heart operation is an independent risk factor for acute renal failure Ann. Thorac. Surg., June 1, 2003; 75(6): 1829 - 1835. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Deng, K. Byth, and H. S Paterson Age and Left Ventricular Impairment Predict Reopening for Bleeding Asian Cardiovasc Thorac Ann, June 1, 2003; 11(2): 147 - 152. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Englberger, B. Kipfer, P. A. Berdat, U. E. Nydegger, and T. P. Carrel Aprotinin in coronary operation with cardiopulmonary bypass: does "low-dose" aprotinin inhibit the inflammatory response? Ann. Thorac. Surg., June 1, 2002; 73(6): 1897 - 1904. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Lemmer Jr and G. J. Despotis Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery J. Thorac. Cardiovasc. Surg., February 1, 2002; 123(2): 213 - 217. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Murkin, J. Maurer, and S. Niemcryk Full dose aprotinin administration is associated with a significant decrease in perioperative stroke in patients undergoing elective cardiac surgery: a meta-analysis Ann. Thorac. Surg., January 1, 2002; 73(1): S374 - 374. [Full Text] [PDF] |
||||
![]() |
G. J. Despotis, M. S. Avidan, and C. W. Hogue Jr Mechanisms and attenuation of hemostatic activation during extracorporeal circulation Ann. Thorac. Surg., November 1, 2001; 72(5): S1821 - 1831. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Murkin Attenuation of neurologic injury during cardiac surgery Ann. Thorac. Surg., November 1, 2001; 72(5): S1838 - 1844. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Alvarez, L. R. Jackson, C. Chatwin, and J. J. Smolich Low-dose postoperative aprotinin reduces mediastinal drainage and blood product use in patients undergoing primary coronary artery bypass grafting who are taking aspirin: A prospective, randomized, double-blind, placebo-controlled trial J. Thorac. Cardiovasc. Surg., September 1, 2001; 122(3): 457 - 463. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Ray, M. M. Hales, L. Brown, M. F. O'Brien, and E. G. Stafford Postoperatively administered aprotinin or epsilon aminocaproic acid after cardiopulmonary bypass has limited benefit Ann. Thorac. Surg., August 1, 2001; 72(2): 521 - 526. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Ascione, S. Williams, C. T. Lloyd, T. Sundaramoorthi, A. A. Pitsis, and G. D. Angelini Reduced postoperative blood loss and transfusion requirement after beating-heart coronary operations: A prospective randomized study J. Thorac. Cardiovasc. Surg., April 1, 2001; 121(4): 689 - 696. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Dignan, D. W. Law, P. W. Seah, C. W. Manganas, D. C. Newman, P. W. Grant, and H. D. Wolfenden Ultra-low dose aprotinin decreases transfusion requirements and is cost effective in coronary operations Ann. Thorac. Surg., January 1, 2001; 71(1): 158 - 164. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Ascione, M. Caputo, G. Calori, C. T. Lloyd, M. J. Underwood, and G. D. Angelini Predictors of Atrial Fibrillation After Conventional and Beating Heart Coronary Surgery : A Prospective, Randomized Study Circulation, September 26, 2000; 102(13): 1530 - 1535. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Casati, D. Guzzon, M. Oppizzi, F. Bellotti, A. Franco, C. Gerli, M. Cossolini, G. Torri, G. Calori, S. Benussi, et al. Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: Effects on perioperative bleeding and allogeneic transfusions J. Thorac. Cardiovasc. Surg., September 1, 2000; 120(3): 520 - 527. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Ascione, C. T. Lloyd, M. J. Underwood, A. A. Lotto, A. A. Pitsis, and G. D. Angelini Inflammatory response after coronary revascularization with or without cardiopulmonary bypass Ann. Thorac. Surg., April 1, 2000; 69(4): 1198 - 1204. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. V Moran, G. Lema, J. Medel, M. J Irarrazaval, R. Zalaquett, B. Garayar, and R. Flaskamp Comparison of two doses of aprotinin in patients receiving aspirin before coronary bypass surgery Perfusion, March 1, 2000; 15(2): 105 - 110. [Abstract] [PDF] |
||||
![]() |
B. P. Bidstrup, B. J. Hunt, S. Sheikh, R. N. Parratt, J. M. Bidstrup, and R. N. Sapsford Amelioration of the bleeding tendency of preoperative aspirin after aortocoronary bypass grafting Ann. Thorac. Surg., February 1, 2000; 69(2): 541 - 547. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. B. Berger, E. L. Alderman, A. Nadel, and H. V. Schaff Frequency of Early Occlusion and Stenosis in a Left Internal Mammary Artery to Left Anterior Descending Artery Bypass Graft After Surgery Through a Median Sternotomy on Conventional Bypass : Benchmark for Minimally Invasive Direct Coronary Artery Bypass Circulation, December 7, 1999; 100(23): 2353 - 2358. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Ascione, C. T. Lloyd, M. J. Underwood, A. A. Lotto, A. A. Pitsis, and G. D. Angelini Economic outcome of off-pump coronary artery bypass surgery: a prospective randomized study Ann. Thorac. Surg., December 1, 1999; 68(6): 2237 - 2242. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. O’Connor, D. V. Brown, M. Avramov, S. Barnes, H. N. O’Connor, and K. J. Tuman The Impact of Renal Dysfunction on Aprotinin Pharmacokinetics During Cardiopulmonary Bypass Anesth. Analg., November 1, 1999; 89(5): 1101 - 1101. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Ray, K. F. Brown, C. A. Burrows, and M. F. O’Brien Economic evaluation of high-dose and low-dose aprotinin therapy during cardiopulmonary bypass Ann. Thorac. Surg., September 1, 1999; 68(3): 940 - 945. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M.H. Khan, N. Gikakis, S. Miyamoto, A. K. Rao, S. L. Cooper, L. H. Edmunds Jr, and R. W. Colman Aprotinin inhibits thrombin formation and monocyte tissue factor in simulated cardiopulmonary bypass Ann. Thorac. Surg., August 1, 1999; 68(2): 473 - 478. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Ascione, C. T. Lloyd, M. J. Underwood, W. J. Gomes, and G. D. Angelini On-pump versus off-pump coronary revascularization: evaluation of renal function Ann. Thorac. Surg., August 1, 1999; 68(2): 493 - 498. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Alonso, C. W. Whitten, and G. E. Hill Pump prime only aprotinin inhibits cardiopulmonary bypass-induced neutrophil CD11b up-regulation Ann. Thorac. Surg., February 1, 1999; 67(2): 392 - 395. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Munoz, N. J. O. Birkmeyer, J. D. Birkmeyer, G. T. O'Connor, and L. J. Dacey Is {epsilon}-Aminocaproic Acid as Effective as Aprotinin in Reducing Bleeding With Cardiac Surgery? : A Meta-Analysis Circulation, January 12, 1999; 99(1): 81 - 89. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. B. Rich The efficacy and safety of aprotinin use in cardiac surgery Ann. Thorac. Surg., November 1, 1998; 66(90050): S6 - 11. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Misfeld, S. Dubbert, S. Eleftheriadis, H.-J. Siemens, T. Wagner, and H.-H. Sievers Fibrinolysis-adjusted perioperative low-dose aprotinin reduces blood loss in bypass operations Ann. Thorac. Surg., September 1, 1998; 66(3): 792 - 799. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Mannucci Hemostatic Drugs N. Engl. J. Med., July 23, 1998; 339(4): 245 - 253. [Full Text] [PDF] |
||||
![]() |
H. Mossinger and W. Dietrich Activation of Hemostasis During Cardiopulmonary Bypass and Pediatric Aprotinin Dosage Ann. Thorac. Surg., June 1, 1998; 65(90060): S45 - 51. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Dietrich, K. Schopf, M. Spannagl, M. Jochum, S. L. Braun, and H. Meisner Influence of High- and Low-Dose Aprotinin on Activation of Hemostasis in Open Heart Operations Ann. Thorac. Surg., January 1, 1998; 65(1): 70 - 77. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Westaby Aprotinin Fifteen Years Later Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 1997; 1(4): 366 - 375. [Abstract] [PDF] |
||||
![]() |
D. Royston Hemostatic Drugs in Prothrombotic or Hypercoagulable States Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 1997; 1(4): 376 - 394. [Abstract] [PDF] |
||||
![]() |
R. R. Lazzara, F. E. Kidwell, M. F. Kraemer, J. A. Wood, and A. Starr Reduction in Costs, Blood Products, and Operating Time in Patients Undergoing Open Heart Surgery Arch Surg, August 1, 1997; 132(8): 858 - 861. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |